Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 323

1.

Rise and fall of an anti-MUC1 specific antibody.

Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, Schirrmann T, Esteves IT, Behrens CK, Fournes B, Fournier N, de Romeuf C, Hust M, Dübel S.

PLoS One. 2011 Jan 14;6(1):e15921. doi: 10.1371/journal.pone.0015921.

2.

Menopausal hormone therapy and risk of clinical breast cancer subtypes.

Slanger TE, Chang-Claude JC, Obi N, Kropp S, Berger J, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Flesch-Janys D.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1188-96. doi: 10.1158/1055-9965.EPI-09-0002. Epub 2009 Mar 31.

3.

Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up.

Hölscher G, Anthuber C, Bastert G, Burges A, Mayr D, Oberlechner E, Schubert-Fritschle G, Sinz S, Sommer H, Schmalfeldt B, Engel J; 'Malignant Ovarian Tumors' of the Munich Cancer Center (MCC).

Acta Obstet Gynecol Scand. 2009;88(4):440-8. doi: 10.1080/00016340902741208.

PMID:
19191075
4.

Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas.

Marmé A, Zimmermann HP, Moldenhauer G, Schorpp-Kistner M, Müller C, Keberlein O, Giersch A, Kretschmer J, Seib B, Spiess E, Hunziker A, Merchán F, Möller P, Hahn U, Kurek R, Marmé F, Bastert G, Wallwiener D, Ponstingl H.

Int J Cancer. 2008 Nov 1;123(9):2048-56. doi: 10.1002/ijc.23763.

5.

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.

Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, Schuetz F.

Ann Oncol. 2008 Dec;19(12):2007-11. doi: 10.1093/annonc/mdn429. Epub 2008 Jul 29.

6.

Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy.

Flesch-Janys D, Slanger T, Mutschelknauss E, Kropp S, Obi N, Vettorazzi E, Braendle W, Bastert G, Hentschel S, Berger J, Chang-Claude J.

Int J Cancer. 2008 Aug 15;123(4):933-41. doi: 10.1002/ijc.23655.

7.

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.

Krainick-Strobel UE, Lichtenegger W, Wallwiener D, Tulusan AH, Jänicke F, Bastert G, Kiesel L, Wackwitz B, Paepke S.

BMC Cancer. 2008 Feb 26;8:62. doi: 10.1186/1471-2407-8-62.

8.

Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates.

Inzkirweli N, Gückel B, Sohn C, Wallwiener D, Bastert G, Lindner M.

Anticancer Res. 2007 Jul-Aug;27(4B):2121-9.

9.

Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.

Schuetz F, Diel IJ, Pueschel M, von Holst T, Solomayer EF, Lange S, Sinn P, Bastert G, Sohn C.

Am J Obstet Gynecol. 2007 Apr;196(4):342.e1-9.

PMID:
17403414
10.

Preeclampsia: increased expression of soluble ADAM 12.

Gack S, Marmé A, Marmé F, Wrobel G, Vonderstrass B, Bastert G, Lichter P, Angel P, Schorpp-Kistner M.

J Mol Med (Berl). 2005 Nov;83(11):887-96. Epub 2005 Oct 25.

PMID:
16247621
11.

Neoadjuvant therapy with gemcitabine in breast cancer.

Schneeweiss A, Bastert G, Huober J, Wallwiener D, Hamerla R, Lichter P.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 12):27-31.

12.
13.
14.

Endoscopic stenting of the common bile duct allows successful treatment of a breast cancer patient with excessive liver metastases.

Eichbaum MH, Schneeweiss A, de Rossi T, Bastert G.

Am J Clin Oncol. 2004 Dec;27(6):642-3.

PMID:
15577448
15.

Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy.

Schneeweiss A, Diel I, Hensel M, Kaul S, Sinn HP, Unnebrink K, Rudlowski C, Lauschner I, Schuetz F, Egerer G, Haas R, Ho AD, Bastert G.

Ann Oncol. 2004 Nov;15(11):1627-32.

16.

Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.

Schneeweiss A, Huober J, Sinn HP, von Fournier D, Rudlowski C, Beldermann F, Krauss K, Solomayer E, Hamerla R, Wallwiener D, Bastert G.

Eur J Cancer. 2004 Nov;40(16):2432-8.

PMID:
15519516
17.

Risk factors in alcohol associated breast cancer: alcohol dehydrogenase polymorphism and estrogens.

Coutelle C, Höhn B, Benesova M, Oneta CM, Quattrochi P, Roth HJ, Schmidt-Gayk H, Schneeweiss A, Bastert G, Seitz HK.

Int J Oncol. 2004 Oct;25(4):1127-32.

PMID:
15375565
18.

Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.

Beckhove P, Feuerer M, Dolenc M, Schuetz F, Choi C, Sommerfeldt N, Schwendemann J, Ehlert K, Altevogt P, Bastert G, Schirrmacher V, Umansky V.

J Clin Invest. 2004 Jul;114(1):67-76.

19.
20.

DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri.

Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M.

Clin Cancer Res. 2004 May 1;10(9):3059-63.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk